share_log

ChemoCentryx, Inc. (NASDAQ:CCXI) Receives Consensus Rating of "Hold" From Brokerages

ChemoCentryx, Inc. (NASDAQ:CCXI) Receives Consensus Rating of "Hold" From Brokerages

ChemoCentryx，Inc.(纳斯达克代码：CCXI)获得券商一致给予的“持有”评级
Defense World ·  2022/09/14 02:42

ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) has earned a consensus rating of "Hold" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $62.43.

据市场评级公司报道，ChemoCentryx，Inc.(纳斯达克代码：CCXI-GET Rating)已获得目前涵盖该股的九家评级公司的共识评级为“持有”。六位分析师对该股的评级为持有，两位分析师给出了买入评级，一位分析师对该公司给予了强烈的买入评级。去年更新了该股覆盖范围的经纪商的平均12个月目标价为62.43美元。

Several equities analysts have recently issued reports on CCXI shares. StockNews.com raised shares of ChemoCentryx from a "sell" rating to a "hold" rating in a research note on Wednesday, August 10th. HC Wainwright cut shares of ChemoCentryx from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $101.00 to $52.00 in a research report on Friday, August 5th. Canaccord Genuity Group initiated coverage on shares of ChemoCentryx in a research report on Thursday, August 4th. They set a "buy" rating and a $81.00 price objective for the company. Stifel Nicolaus cut shares of ChemoCentryx from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th. Finally, Canaccord Genuity Group cut shares of ChemoCentryx from a "buy" rating to a "hold" rating and set a $52.00 price objective for the company. in a research report on Friday, August 5th.

几位股票分析师最近发布了关于CCXI股票的报告。在8月10日星期三的一份研究报告中，股票新闻网站将ChemoCentryx的股票评级从“卖出”上调为“持有”。8月5日，在一份研究报告中，HC Wainwright将ChemoCentryx的股票评级从“买入”下调至“中性”，并将其股票目标价从101.00美元下调至52美元。Canaccel Genuity集团在8月4日星期四的一份研究报告中启动了对ChemoCentryx股票的报道。他们为该公司设定了“买入”评级和81.00美元的目标价。在8月10日星期三的一份研究报告中，Stifel Nicolaus将ChemoCentryx的股票评级从“买入”下调至“持有”。最后，Canaccel Genuity Group将ChemoCentryx的股票评级从“买入”下调至“持有”，并为该公司设定了52.00美元的目标价。在8月5日星期五的一份研究报告中。

Get
到达
ChemoCentryx
ChemoCentryx
alerts:
警报：

ChemoCentryx Price Performance

ChemoCentryx性价比

CCXI stock opened at $51.37 on Wednesday. The company has a fifty day moving average price of $39.43 and a 200-day moving average price of $28.74. The company has a market capitalization of $3.67 billion, a P/E ratio of -27.18 and a beta of 1.25. ChemoCentryx has a 52-week low of $14.95 and a 52-week high of $51.78. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.54.

CCXI股价周三开盘报51.37美元。该公司的50日移动均价为39.43美元，200日移动均价为28.74美元。该公司市值为36.7亿美元，市盈率为-27.18，贝塔系数为1.25。ChemoCentryx的52周低点为14.95美元，52周高点为51.78美元。该公司的负债权益比率为0.02，速动比率为4.47，流动比率为4.54。

Insider Activity

内幕活动

In other news, CEO Thomas J. Schall sold 130,000 shares of ChemoCentryx stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the completion of the transaction, the chief executive officer now directly owns 2,393,352 shares in the company, valued at $120,242,004.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Susan M. Kanaya sold 46,298 shares of the firm's stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $50.17, for a total transaction of $2,322,770.66. Following the transaction, the chief financial officer now directly owns 91,317 shares of the company's stock, valued at $4,581,373.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas J. Schall sold 130,000 shares of the firm's stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the transaction, the chief executive officer now directly owns 2,393,352 shares in the company, valued at $120,242,004.48. The disclosure for this sale can be found here. Insiders sold 213,760 shares of company stock worth $10,749,838 over the last three months. 8.30% of the stock is currently owned by insiders.
其他消息方面，首席执行官托马斯·J·舒尔在一笔日期为8月4日星期四的交易中出售了13万股ChemoCentryx股票。这些股票以50.24美元的平均价格出售，总成交金额为6,531,200.00美元。交易完成后，首席执行官现在直接拥有该公司2,393,352股，价值120,242,004.48美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过以下链接访问该文件。在相关新闻中，首席财务官Susan M.Kanaya在一笔日期为8月4日(星期四)的交易中出售了46,298股该公司股票。这些股票的平均价格为50.17美元，总成交额为2,322,770.66美元。交易完成后，首席财务官现在直接持有该公司91,317股股票，价值4,581,373.89美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，可以通过美国证券交易委员会网站访问该文件。此外，首席执行官托马斯·J·沙尔在一笔日期为8月4日(星期四)的交易中出售了13万股公司股票。这些股票以50.24美元的平均价格出售，总成交金额为6,531,200.00美元。交易完成后，这位首席执行官现在直接持有该公司2393,352股股票，价值120,242,004.48美元。此次拍卖的披露信息可在此处找到。过去三个月，内部人士出售了213,760股公司股票，价值10,749,838美元。该公司8.30%的股份目前由内部人士持有。

Institutional Inflows and Outflows

机构资金流入和流出

Large investors have recently made changes to their positions in the company. Engineers Gate Manager LP raised its position in ChemoCentryx by 4.4% in the first quarter. Engineers Gate Manager LP now owns 12,780 shares of the biopharmaceutical company's stock worth $320,000 after acquiring an additional 540 shares during the period. Teacher Retirement System of Texas raised its position in ChemoCentryx by 9.2% in the first quarter. Teacher Retirement System of Texas now owns 9,999 shares of the biopharmaceutical company's stock worth $251,000 after acquiring an additional 841 shares during the period. UBS Asset Management Americas Inc. raised its position in ChemoCentryx by 1.4% in the second quarter. UBS Asset Management Americas Inc. now owns 69,953 shares of the biopharmaceutical company's stock worth $1,733,000 after acquiring an additional 971 shares during the period. Victory Capital Management Inc. raised its position in ChemoCentryx by 7.5% in the second quarter. Victory Capital Management Inc. now owns 14,077 shares of the biopharmaceutical company's stock worth $349,000 after acquiring an additional 981 shares during the period. Finally, Level Four Advisory Services LLC raised its position in ChemoCentryx by 10.9% in the first quarter. Level Four Advisory Services LLC now owns 13,016 shares of the biopharmaceutical company's stock worth $326,000 after acquiring an additional 1,276 shares during the period. 81.09% of the stock is owned by institutional investors.

大型投资者最近对他们在该公司的头寸进行了调整。工程师门经理LP在第一季度将其在ChemoCentryx的头寸提高了4.4%。工程师门管理公司现在拥有12,780股这家生物制药公司的股票，价值32万美元，在此期间又购买了540股。德克萨斯州教师退休系统第一季度将其在ChemoCentryx的职位提高了9.2%。德克萨斯州教师退休系统在此期间额外购买了841股，现在拥有9999股这家生物制药公司的股票，价值251,000美元。瑞银资产管理美洲公司(UBS Asset Management America Inc.)第二季度将其在ChemoCentryx的持仓提高了1.4%。瑞银资产管理美洲公司(UBS Asset Management America Inc.)目前持有69,953股这家生物制药公司的股票，价值1,733,000美元，在此期间又购买了971股。胜利资本管理公司在第二季度将其在ChemoCentryx的持仓提高了7.5%。胜利资本管理公司现在拥有14,077股这家生物制药公司的股票，价值349,000美元，在此期间又购买了981股。最后，Level Four Consulting Services LLC在第一季度将其在ChemoCentryx的头寸提高了10.9%。Level Four Consulting Services LLC在此期间额外收购了1,276股，现在拥有这家生物制药公司13,016股股票，价值326,000美元。81.09%的股份由机构投资者持有。

ChemoCentryx Company Profile

ChemoCentryx公司简介

(Get Rating)

(获取评级)

ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

ChemoCentryx，Inc.是一家生物制药公司，专注于在美国开发和商业化治疗炎症性疾病、自身免疫性疾病和癌症的新药。它提供TAVNEOS(Avacopan)，一种口服的选择性C5aR抑制剂，用于治疗严重的抗中性粒细胞胞浆抗体相关小血管炎的成人患者。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
  • These 3 Reports Will Tell Us Much About the Current Economy
  • Is Five Below Trying to Punch Too High?
  • This Is What To Expect From The S&P 500 Now
  • The Two Things You Need To Know About Oracle's FQ1 Report
  • Three Value Stocks For A Volatile Market
  • 免费获取StockNews.com关于ChemoCentryx(CCXI)的研究报告
  • 这三份报告将告诉我们许多关于当前经济的情况。
  • 下面的五个是不是打得太高了？
  • 这就是现在对标准普尔500指数的预期
  • 关于甲骨文的FQ1报告，你需要知道的两件事
  • 波动市场的三只价值股

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.

接受ChemoCentryx日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ChemoCentryx和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发